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Context: Early prediction of dysglycemia is crucial to prevent progression to type 2 diabetes. The
1-hour postload plasma glucose (PG) is reported to be a better predictor of dysglycemia than fasting
plasma glucose (FPG), 2-hour PG, or glycated hemoglobin (HbA1c).
Objective: To evaluate the predictive performance of clinical markers, metabolites, HbA1c, and PG
and serum insulin (INS) levels during a 75-g oral glucose tolerance test (OGTT).
Design and Setting:Wemeasured PG and INS levels at 0, 30, 60, and 120minutes during an OGTT in
543 participants in the Botnia Prospective Study, 146 of whom progressed to type 2 diabetes
within a 10-year follow-up period. Using combinations of variables, we evaluated 1527 predictive
models for progression to type 2 diabetes.
Results: The 1-hour PG outperformed every individual marker except 30-minute PG or mannose,
whose predictive performances were lower but not significantly worse. HbA1c was inferior to
1-hour PG according to DeLong test P value but not false discovery rate. Combining the metabolic
markers with PG measurements and HbA1c significantly improved the predictive models, and
mannose was found to be a robust metabolic marker.
Conclusions: The 1-hour PG, alone or in combination with metabolic markers, is a robust predictor
for determining the future risk of type 2 diabetes, outperforms the 2-hour PG, and is cheaper to
measure thanmetabolites.Metabolites add to the predictive value of PG andHbA1cmeasurements.
Shortening the standard 75-g OGTT to 1 hour improves its predictive value and clinical usability.
(J Clin Endocrinol Metab 104: 1131–1140, 2019)
Because type 2 diabetes may be a preventable disease(1), early prediction is crucial. Fasting plasma glucose
(FPG) and 2-hour plasma glucose (PG) after the 75-g oral
glucose tolerance test (OGTT) are used to assess the risk
of developing type 2 diabetes. Several recent studies have
demonstrated that 1-hour postload PG is a better predictor
of dysglycemia than FPG, 2-hour PG, or glycated hemo-
globin (HbA1c) (2) and that 1-hour PG is predictive of not
only type 2 diabetes but also cardiovascular disease and
mortality (3–7). Furthermore, the CATAMERI study found
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that peoplewith normal glucose tolerance having an elevated
1-hour PG level $8.6 mmol/L were at higher risk for de-
veloping chronic kidney disease (8), nonalcoholic fatty liver
disease (9), increased vascular stiffness (10), and early
carotid atherosclerosis (11). An elevated 1-hour PG
level was also associated with decreased insulin (INS)
clearance (12), INS sensitivity, and reduced b-cell
function (13), an unfavorable inflammatory profile
(14), and whole blood viscosity (15).
Meanwhile, metabolomics has also provided a rich
source of predictive markers for future progression to
type 2 diabetes (16, 17). A number of prospective studies
identified metabolic biomarkers including branched chain
and aromatic amino acids, sugars and carbohydrates,
and lipids (phospholipids, triglycerides) to be associated
with the incidence of prediabetes (ie, impaired glucose
tolerance, impaired fasting glucose, INS resistance, or im-
paired INS sensitivity) and type 2 diabetes (17). Using mass
spectrometry-based metabolomics in a Botnia Pro-
spective Study (BPS) cohort, we previously performed a
systematic assessment of metabolites in predicting fu-
ture progression to type 2 diabetes and identified seven
metabolic markers that provided the best predictive
model in combination with clinical risk factors (18).
These metabolic markers included glucose, mannose,
a-hydroxybutyrate (AHB), a-tocopherol, bradykinin-
hydroxyproline ([Hyp3]-BK), and the unknown me-
tabolites X-12063 and X-13435, the latter of which was
identified as 10:1 carnitine during this study.
Given the predictive performance of OGTT-derived
PG measurements and metabolites, we hypothesized that
combining PG measurements with metabolites would
further improve prediction of future risk for type 2 di-
abetes. Therefore, we performed a systematic assessment
of the predictive performance of PG levels measured at
different time points during the OGTT, HbA1c, meta-
bolic markers, and clinical risk factors such as age, sex,
body mass index (BMI), and familial history (FH) of type
2 diabetes, and we considered the clinical translatability
of our findings. Although the predictive performance of
PG values and metabolites has been studied previously,
the novelty of our contribution is in providing a sys-
tematic assessment of their joint predictive performance
for future progression to type 2 diabetes.
Materials and Methods
Study population
The BPS, initiated in 1990 on the west coast of Finland,
includes a cohort of 2770 nondiabetic people followed for 10 years
(median 7.7 years), 150 of whom developed type 2 diabetes
(19). In the current study, we included a BPS subpopulation of
543 participants, including 146 who progressed to type 2
diabetes (called progressors) by the end of the follow-up pe-
riod [Table D1 in (20)], in whom serum metabolomics data
were available (18). The control sample of 397 participants in
the current study was randomly chosen from among the 2620
nonprogressors.
Helsinki University Central Hospital approved the study
protocols. All participants gave informed consent to their
participation in the study.
OGTT
All participants underwent a 75-g OGTT after a 12-hour
overnight fast. Participants were instructed to eat and exercise
normally for 3 days before the OGTT. PG levels were measured
at 0, 30, 60, and 120 minutes during the OGTT via the glucose
oxidase method (Beckman Glucose Analyzer, Beckman In-
struments, Fullerton, CA). Serum INS levels during the OGTT
were measured by RIA (Linco; Pharmacia, Uppsala, Sweden) or
an enzyme immunoassay (DAKO, Cambridgeshire, UK); the
correlation between the methods after conversion was 0.98
(P , 0.0001).
Clinical risk factors and diagnostic criteria
Sex, age, BMI, and FH were recorded at baseline. HbA1c
was measured via high-performance liquid chromatography.
The World Health Organization criteria (21) were used to
define impaired fasting glucose (IFG; 6.1 mmol/L # FPG ,
7.0 mmol/L and 2-hour PG , 7.8 mmol/L) and impaired
glucose tolerance (IGT; FPG , 7.0 mmol/L and 7.8 mmol/L #
2-hour PG , 11.1 mmol/L) [Table D1 in (20)]. With this, we
determined that 86 participants had IFG, 112 had IGT, and 324
had neither at the baseline.
The World Health Organization diagnostic criteria (FPG
$7.0 mmol/L or 2-hour PG$11.1 mmol/L) were used to define
whether a participant had progressed to type 2 diabetes based
on a 75-g OGTT during the final follow-up visit for the
participant.
Statistical analysis
In this study, participants with missing measurements for
any variable were excluded from all analyses involving that
particular variable. To test the association of a variable with
progression to type 2 diabetes, the Fisher exact test was used for
categorical variables, and the Welch t test was used for con-
tinuous variables [Table D1 in (20)]. Correlation between
continuous variables was tested with the Pearson correlation
test [Tables D2 and D3 in (20)].
Metabolomics and identification of
metabolic markers
Ferrannini et al. (22) applied a clinically validated targeted
metabolomics assay to measure two metabolites—AHB and
1-linoleoyl glycerophosphocholine—in a larger BPS subpop-
ulation (n = 2580) than the current study (n = 543). In
contrast, the current study used a combination of global
untargeted and targeted metabolomics approaches and mea-
sured 568 metabolites. Fasting serum samples collected at
baseline were used for metabolomic profiling performed at
Metabolon Inc. (Durham,NC). Samples were preparedwith the
single extraction method and were subjected to untargeted and
targeted metabolomics, via ultra-high-performance liquid
chromatography or gas chromatography coupled with mass
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spectrometry and isotope-dilution ultra-high-performance liq-
uid chromatography coupled with tandem mass spectrometry,
respectively (18). Metabolites were identified by automated
spectral comparison with a standard library, and missing values
were imputed with minimum nonmissing measurement. The
targeted and untargeted metabolomics data were standardized
to zero mean and unit variance per metabolite and combined
into a single data matrix containing 568 metabolite measure-
ments from 543 samples.
A metabolic marker panel consisting of glucose, mannose,
AHB, [Hyp3]-BK, a-tocopherol, and the unknown metabo-
lites X-13435 and X-12063 was derived with a machine
learning–based feature selection approach, as described pre-
viously (18). Using updated mass spectral identification li-
braries, Metabolon Inc. identified X-13435 as 10:1 carnitine
during this study.
Predictive models
We evaluated predictive performances of various combina-
tions (n = 1527) of clinical risk factors, PG, and INS levels during
OGTT, HbA1c, and six metabolic markers (mannose, AHB,
[Hyp3]-BK, a-tocopherol, 10:1 carnitine, and X-12063) via
machine learning–based predictive models for future progression
to type 2 diabetes. Briefly, a regularized least squares regression
approach (23)was used to build binary classifiers via the repeated
nested cross-validation described in (18) with 100 repetitions.
Average scores from the 100 predictions were calculated to
construct the receiver operating characteristic (ROC) curve. The
optimal classification threshold for the prediction score was
determined from the ROC curve based on the F-index of sen-
sitivity and specificity values. That is, the harmonic mean of
sensitivity and specificity was calculated for each threshold value
on the ROC curve, and the value corresponding to the maximum
harmonic mean was selected as the optimal cutoff. The binary
classification accuracy, sensitivity, specificity, negative predictive
value (NPV), and positive predictive value (PPV) were calculated
at the optimal cutoff. The 95%CI for the area under the receiver
operating characteristic curve (AUC) was computed via
DeLong’s method with 2000 stratified bootstrap replicates (24,
25). Predictive performance of each model was compared with
that of 1-hour PG via DeLong’s test for the comparison of
correlated ROC curves (24). To address the multiple testing
problem arising from the large number (n = 1526) of com-
parisons, q-values were calculated with the positive false dis-
covery rate approach (26). The q-values were rounded to two
decimal digits, and the results with q, 0.05 after the rounding
were considered statistically significant.
Results
Identification of an unknown metabolite
We previously identified a panel of seven meta-
bolic markers—glucose, mannose, AHB, [Hyp3]-BK, a-
tocopherol, and the unidentified metabolites X-13435
and X-12063—by using predictive modeling of se-
rum metabolomics data (18). Reidentification during
the current study with an updated Metabolon mass
spectral identification library identified X-13435 as 10:1
carnitine. Therefore, in this study we refer to X-13435 as
10:1 carnitine.
Correlations between PG measurements
The PG levels significantly correlated with each other.
The consecutive time points showed higher correlations
with each other than with time points further apart. The
FPG showed higher correlation with 30-minute PG, the
30-minute PG with 1-hour PG, and the 2-hour PG with
1-hour PG than with other time points [Table D2 in (20)].
The 30-minute PG and 1-hour PG pair showed the
highest correlation of all PG pairs. HbA1c showed higher
correlation with post-OGTT PG levels than with FPG.
Correlation between glucose measurements and
metabolic markers
Mannose showed higher correlation with the FPG
(Pearson correlation coefficient, r = 0.30) and 30-minute
PG (r = 0.32) than with 1-hour PG (r = 0.26) or 2-hour
PG (r = 0.14). AHB correlated poorly with FPG (r = 0.08)
but more strongly with post-OGTT PG values, showing
the strongest correlation with 1-hour PG (r = 0.37).
[Hyp3]-BK showed the strongest correlation with 1-hour
PG (r = 20.25) and X-12063 with 2-hour PG (r = 0.35).
In contrast, a-tocopherol and 10:1 carnitine were not
associated with PG measurements (Fig. 1). HbA1c
showed higher correlation with mannose (r = 0.16) and
X-12063 (r = 0.16) than with other metabolites [Table
D3 in (20)]. On average, metabolites showed higher
correlation with PG values than with HbA1c.
Predictive models
We used a regularized least squares regression ap-
proach to build predictive models for incident type 2
diabetes by using various combinations of PG (FPG, 30-
minute PG, 1-hour PG, or 2-hour PG) and INS levels
(fasting INS, 30-minute INS, 1-hour INS, and 2-hour
INS), HbA1c, metabolic markers, and clinical risk factors
(age, sex, BMI, and FH), such as (1) combinations of PG
or INS levels (2), combinations of PG levels and common
clinical risk factors (3), combinations of metabolites (4),
combinations of PG levels and metabolites, and (5)
combinations of PG levels, HbA1c, clinical risk factors,
and metabolites. Altogether, we evaluated 1527 pre-
dictive models whose predictive performances are sum-
marized below [see also Tables D4–D10 in (20)].
Predictive models including glucose measurements
Among PGmeasurements, 1-hour PG showed the best
predictive performance for type 2 diabetes, followed by
30-minute PG (Fig. 2). The 1-hour PG (AUC = 0.75,
sensitivity = 0.75, specificity = 0.68) and 30-minute PG
(AUC = 0.71, sensitivity = 0.62, specificity = 0.71) pre-
dicted progression to type 2 diabetes more accurately
than FPG (AUC = 0.63, sensitivity = 0.55, specificity =
0.64) or 2-hour PG (AUC = 0.68, sensitivity = 0.56,
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specificity = 0.73). None of the PG pairs improved
predictive performance beyond the 1-hour PG alone
[Table D4 in (20)]. For instance, the combined model
with 30-minute PG and 1-hour PG (AUC = 0.76, sen-
sitivity = 0.72, specificity = 0.66) or FPG and 2-hour
PG (AUC = 0.70, sensitivity = 0.59, specificity = 0.71)
performed only as well as the model with 1-hour PG
alone (false discovery rate q-value = 0.42 and 0.07, re-
spectively). The combined model with all four PG values
(AUC = 0.77, sensitivity = 0.73, specificity = 0.69, q =
0.31) did not improve prediction beyond 1-hour PG
alone.
Predictive models including clinical risk factors
The model with only the clinical risk factors, age,
sex, BMI, and FH (AUC = 0.66, sensitivity = 0.69,
specificity = 0.55) was clearly worse than 1-hour PG
alone (q = 0.02). Both 30-minute PG and 1-hour PG,
but neither FPG nor 2-hour PG, significantly improved
the predictive performance of the clinical risk factor
model. In particular, combining 1-hour PG and clini-
cal risk factors (AUC = 0.77, sensitivity = 0.77, speci-
ficity = 0.70) improved the predictive performance of
the clinical model (q = 0.02), but not that of 1-hour
PG (q = 0.45).
Predictive models including HbA1c
The model with HbA1c, although showing lower
performance than 1-hour PG (AUC = 0.67, sensitiv-
ity = 0.65, specificity = 0.64, DeLong p-value = 0.03), was
not significantly worse after accounting for multiple
hypothesis testing (q = 0.09). Combining HbA1c with
clinical risk factors or any combination of PG values
did not outperform 1-hour PG alone. In particular, the
combination of HbA1c with clinical risk factors
(AUC = 0.71, sensitivity = 0.68, specificity = 0.67,
q = 0.33), FPG (AUC = 0.70, sensitivity = 0.60, speci-
ficity = 0.71, q = 0.20), or both (AUC = 0.72, sensitivity =
0.55, specificity = 0.80, q = 0.34) resulted in models
comparable with 1-hour PG. The combination of HbA1c
and 1-hour PG (AUC = 0.76, sensitivity = 0.78, speci-
ficity = 0.68) was also comparable to 1-hour PG alone
(q = 0.31) but significantly outperformed HbA1c alone
(q = 0.02).
Figure 2. Comparison of predictive performances by PG
measurements: FPG (green dotted-dash line; AUC 0.63; 95% CI,
0.58 to 0.69), 30-min PG (red dashed line; AUC 0.71; 95% CI,
0.66 to 0.77), 1-h PG (blue continuous line; AUC 0.75; 95% CI,
0.71 to 0.80), and 2-h PG (pink dotted line; AUC 0.68; 95% CI,
0.62 to 0.73). Among the PG measurements, 1-h PG predicted the
incident type 2 diabetes the best followed by 30-min PG (q = 0.02
vs FPG, q = 0.12 vs 30-min PG, and q = 0.03 vs 2-h PG).
Figure 1. Correlation of metabolic markers with PG measurements. The metabolic markers correlated more significantly with 30-min PG and 1-h
PG than with FPG. [Hyp3]-BK (green continuous line) and AHB (red dashed line) showed the strongest correlation with 1-h PG, mannose (blue
dotted line) with 30-min PG, and X-12063 (pink dotted-dash line) with 2-h PG. The a-tocopherol and 10:1 carnitine showed low correlations
with the PG measurements and are not shown in the figure.
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Predictive models including metabolic markers
We evaluated the predictive performance of single
metabolites and combinations of two, three, four, five, or
all six metabolites [Table D5 in (20)]. Mannose was not
significantly worse than 1-hour PG (AUC = 0.70, sen-
sitivity = 0.60, specificity = 0.72, q = 0.16), but 1-hour PG
was superior to every other metabolite. The 1-hour PG
significantly outperformed six multivariate models in-
cluding pairs of metabolites, and one model including
three metabolites (q, 0.05). In contrast, no combination
of metabolites significantly outperformed 1-hour PG
alone. The multivariate model containing all six me-
tabolites was comparable with 1-hour PG (AUC = 0.78,
sensitivity = 0.67, specificity = 0.75, q = 0.27). Com-
bining clinical risk factors with metabolites did not im-
prove the predictive performance beyond 1-hour PG. The
multivariate model including HbA1c and six metabolic
markers (AUC = 0.82, sensitivity = 0.81, specificity =
0.72) outperformed 1-hour PG alone (q = 0.04).
Predictive models including FPG and
metabolic markers
In combination with FPG, no single metabolic marker
outperformed 1-hour PG significantly, nor was the com-
bination of FPG and the six metabolic markers (AUC =
0.78, sensitivity = 0.77, specificity = 0.69) signifi-
cantly better than 1-hour PG (q = 0.21). Adding clin-
ical risk factors to this model did not improve the
model beyond 1-hour PG either (AUC = 0.78, sensi-
tivity = 0.71, specificity = 0.76, q = 0.40). Furthermore,
no combination of FPG, clinical risk factors, and metabolic
markers was significantly better than 1-hour PG.However,
the combination of HbA1c, FPG, and six metabolic
markers outperformed 1-hour PG alone (AUC = 0.82,
sensitivity = 0.79, specificity = 0.71, q = 0.03). The com-
bination of HbA1c, FPG, and five metabolites—AHB,
mannose, a-tocopherol, X-12063, and 10:1 carnitine—
also outperformed 1-hour PG (AUC = 82, sensitivity =
0.76, specificity = 0.74, q = 0.04). No other combination
involving HbA1c, FPG, clinical markers, and metabolic
markers significantly outperformed 1-hour PG [Table D6
in (20)].
Predictive models including 30-minute PG and
metabolic markers
Twenty-four multivariate models involving the com-
bination of HbA1c and 30-minute PG with metabolic
markers outperformed 1-hour PG alone [Table D7 in
(20)]. All of these included HbA1c and at least three
metabolites, and four models included clinical risk fac-
tors. For instance, the combination of HbA1c, 30-minute
PG, and six metabolites outperformed 1-hour PG (AUC =
0.84, sensitivity = 0.75, specificity = 0.79, q = 0.02).
Predictive models including 1-hour PG and
metabolic markers
All combinations of 1-hour PG, HbA1c, metabolic
markers, and clinical risk factors evaluated (n = 252)
showed higher AUC than 1-hour PG alone [ie, AUC .
0.75) [Table D8 in (20)]. Of these, 109 models signifi-
cantly outperformed 1-hour PG (ie, q , 0.05). Among
the 109 models, 42 models included 1-hour PG and
metabolites, 49 models included 1-hour PG, HbA1c, and
metabolites, twomodels included 1-hour PG, clinical risk
factors, and metabolites, and 16 models included 1-hour
PG, HbA1c, clinical risk factors, and metabolites.
The combined model with 1-hour PG and all six
metabolic markers (AUC = 0.82, sensitivity = 0.79,
specificity = 0.77) outperformed 1-hour PG alone (q =
0.02). The combined model with HbA1c, 1-hour PG, and
six metabolic markers (AUC = 0.84, sensitivity = 0.73,
specificity = 0.82) also outperformed 1-hour PG (q =
0.02; Fig. 3). Similarly, the combined model with clinical
risk factors, HbA1c, 1-hour PG, and six metabolic
Figure 3. Comparison of predictive performances between 1-h PG,
six metabolic markers, HbA1c, and their combination. Prediction of
progression to type 2 diabetes with 1-h PG, HbA1c, and metabolic
markers (mannose, AHB, [Hyp3]-BK, a-tocopherol, X-12063, and
10:1 carnitine). ROC curve of the predictive model with 1-h PG
alone (blue continuous line; AUC 0.75; 95% CI, 0.71 to 0.80), the
model with the six metabolic markers (red dashed line; AUC 0.78;
95% CI, 0.73 to 0.82), the model with HbA1c alone (green dotted-
dash line; AUC 0.67; 95% CI, 0.61 to 0.72), and the model with
1-h PG, HbA1c, and the six metabolic markers (pink dotted line;
AUC 0.84; 95% CI, 0.80 to 0.88) are shown. The model with the
metabolic markers was slightly but not significantly better than the
model with 1-h PG alone (q = 0.27). The combined model with 1-h
PG, HbA1c, and the metabolic markers was significantly better than
the model with 1-h PG alone (q = 0.02) or with HbA1c alone (q =
0.02).
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markers (AUC = 0.83, sensitivity = 0.84, specificity =
0.73) also outperformed 1-hour PG (q = 0.03).
Predictive models including 2-hour PG and
metabolic markers
Three multivariate models including HbA1c, 2-hour
PG, and metabolic markers significantly outperformed
1-hour PG alone. For instance, the combination ofHbA1c,
2-hour PG, and six metabolic markers outperformed
1-hour PG (AUC= 0.82, sensitivity = 0.72, 0.80, q = 0.03).
Two other models that included HbA1c, 2-hour PG, and
five metabolites outperformed 1-hour PG [Table D9
in (20)].
Predictive models including INS measurements
The predictive performance of 1-hour PG was supe-
rior to that of fasting INS (q = 0.02), 30-minute INS (q =
0.02), 1-hour INS (q = 0.02), 2-hour INS (q = 0.03), their
pairwise combinations, or their combination with clinical
risk factors [Table D10 in (20)]. On the other hand, 67
out of 220 models that included INS variables showed
higher AUC than 1-hour PG but did not provide sig-
nificant improvement.
Improvement of predictive performance due to
1-hour PG or HbA1c
We evaluated whether adding 1-hour PG significantly
improved the predictive performance of 252 multivariate
models involving combinations of HbA1c, clinical risk
factors, and metabolic markers. The addition of 1-hour
PG improved the predictive performance of 184 models,
in particular every combination of metabolites with or
without the clinical risk factors [Table D11 in (20)]. For
instance, the combination of 1-hour PG and six me-
tabolites outperformed combination of six metabolites
(q = 0.01). Of 252models evaluated, however, 1-hour PG
did not significantly improve the performance of 68
models [Table D11 in (20)], which involved either a
combination of HbA1c and clinical risk factors (n = 55)
or just HbA1c (n = 13) with metabolic markers. In
contrast, addition of HbA1c alone did not significantly
improve the performance of any of the models [Table
D12 in (20)].
Predictive models in individuals with IFG or IGT
at baseline
Among the 543 participants in our study, 324 had
neither IFG nor IGT at the beginning of the study (called
IFG/IGT-free group), and 198 participants had either
IFG or IGT (called IFG/IGT group) [Table D1 in (20)]. To
verify whether our results are valid independent of IFG or
IGT status at baseline, we tested whether the predictive
performance of postload PG values follows the same
trend as in the entire population and whether combining
metabolic markers would improve the predictive per-
formance of 1-hour PG or HbA1c.
The 1-hour PG outperformed FPG (P = 0014) and
2-hour PG (P = 0.016) andwas slightly but not significantly
better than 30-minute PG (P = 0.46) or HbA1c (P = 0.09)
in predicting the future progression to type 2 diabetes in
the IFG/IGT-free group [Fig. D1 in (20)]. However, in the
IFG/IGT group 1-hour PG outperformed FPG (P = 0.006)
and was comparable to 30-minute PG (P = 0.05), 2-hour
PG (P = 0.12), and HbA1c (P = 0.62) [Fig. D3 in (20)].
The multivariate model with metabolic markers alone
was comparable to 1-hour PG alone in the IFG/IGT-free
group (P = 0.07) and in the IFG/IGT group (P = 0.72).
The multivariate model combining the 1-hour PG,
HbA1c, and metabolic markers was significantly better
than 1-hour PG (P = 0.01) and HbA1c (P = 0.001) in the
IFG/IGT-free [Fig. D2 in (20)] group as well as in the IFG/
IGT group (P = 0.004 and 0.0006, respectively) [Fig. D4
in (20)].
Discussion
The FPG and 2-hour PG after a 75-g OGTT have tra-
ditionally been used to identify people at risk for de-
veloping type 2 diabetes. More recently, 1-hour PG
level$8.6 mmol/L has been shown to be a more sensitive
biomarker of dysglycemia than FPG, 2-hour PG, or
HbA1c (2). On the other hand, metabolomics has
provided a rich source of biomarkers for the prediction of
type 2 diabetes (16–18). The aim of this study was to
provide a systematic assessment of the joint predictive
performance of metabolic markers and PG levels mea-
sured at different time points during the OGTT. We
constructed machine learning predictive models based on
combinations of PG and INS values, other clinical risk
factors, HbA1c, and metabolic markers that we pre-
viously reported (18), thereby evaluating the perfor-
mance of 1527 models.
Consistent with previous reports, 1-hour PG alone
showed superior predictive performance (AUC = 0.75,
sensitivity = 0.75, specificity = 0.68) to clinical risk
factors (false discovery rate q-value = 0.02), FPG (q =
0.02), and 2-hour PG (q = 0.03) but not 30-minute PG
(q = 0.12) or HbA1c (q = 0.09). Based on an analysis of
1949 participants from the BPS, of whom 132 progressed
to type 2 diabetes during an average follow-up period of
4.94 years, Alyass et al. (3) showed that 1-hour PG
outperformed HbA1c in predicting the future progres-
sion to type 2 diabetes. Our results indicate that the
difference between 1-hour PG and HbA1c was marginal
(q = 0.09). However, with regard to the comparison
between 1-hour PG and HbA1c, the difference between
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our analysis and that of Alyass et al. (3) is due to the
simultaneous comparison of 1526 predictive models with
1-hour PG in our study, which required an assessment of
the statistical difference in light of multiple testing. The
P value derived from the DeLong test of ROC curves
between 1-hour PG and HbA1c in our study is 0.03,
which would have been deemed a significant difference in
the absence of an exhaustive evaluation of a large number
of competing predictive models. Alyass et al. (3) observed
an AUC of 0.80 (95% CI, 0.77 to 0.84) for 1-hour PG in
the BPS cohort and an AUC of 0.70 (95% CI, 0.68 to
0.73) in the Malmö Preventive Project (MPP) study, in
which the follow-up period was 23.5 years. They
therefore postulated that 1-hour PG may better predict
the type 2 diabetes risk in the short term. Our result for
1-hour PG with an AUC of 0.75 (95% CI, 0.71 to 0.80)
during the 10-year follow-up period appears to be in
agreement with the hypothesis. The AUC derived from
HbA1c in our study, 0.67 (95% CI, 0.61 to 0.72), is
comparable to the AUC of 0.69 (95% CI, 0.64 to 0.74)
Alyass et al. (3) derived for HbA1c. Thus, we believe that
our results are in agreement with those of Alyass et al. (3),
and the statistical discrepancy concerning the difference
betweenHbA1c and 1-hour PG is primarily a result of the
difference in the number of hypotheses tested and sec-
ondarily may stem from the differences in the number of
samples and the follow-up period. Abdul-Ghani et al.
(27) previously showed that although HbA1c is a weaker
predictor of progression to type 2 diabetes than 1-hour
PG, combining HbA1c and 1-hour PG together improves
the predictive performance of the latter. Our results
showed that the combination of HbA1c and 1-hour PG
was significantly better than HbA1c (q = 0.02) but not
1-hour PG (q = 0.31).
However, the results of the current study indicate that
HbA1c is indeed a robust predictor of progression to type
2 diabetes in combination with clinical risk factors, PG
measurements, and metabolic markers. For instance,
although the predictive models including clinical risk
factors alone and FPG alone both clearly showed lower
performance than 1-hour PG (ie, q , 0.05), in combi-
nation with HbA1c both the models became comparable
to 1-hour PG (ie, q $ 0.05). Second, the difference be-
tween 1-hour PG and HbA1c was insignificant in the
IFG/IGT and IFG/IGT-free groups, although the one-to-
one DeLong P-value in the whole population was 0.03.
Third, among the 139 predictive models that out-
performed 1-hour PG, 95 models contained HbA1c as a
variable. Moreover, the combination of HbA1c alone
with six metabolic markers (without any other PG var-
iable) outperformed 1-hour PG.
Of all 1527 predictive models evaluated in this study,
139 models outperformed 1-hour PG in terms of AUC
(q , 0.05). All these models included at least one me-
tabolite as a variable. Besides the metabolites, the ad-
dition of HbA1c alone, 1-hour PG alone, 1-hour PG and
clinical risk factors, or HbA1c and a PG measurement
was necessary to achieve a higher predictive performance
than 1-hour PG alone. The 1-hour PG significantly im-
proved predictive performance of all multivariate models
of metabolites [Table D11 in (20)], whereas HbA1c did
not [Table D12 in (20)].
Although the DeLong test allows a formal comparison
of the ROC curves, other statistics such as sensitivity and
specificity are more useful in clinical practice. The 1-hour
PG showed a good balance between sensitivity (0.75) and
specificity (0.68). Of the 139 predictive models that
outperformed 1-hour PG in terms of DeLong comparison
of the ROC curves, 74 showed greater sensitivity than
1-hour PG, 132 showed greater specificity, 68 showed
both greater sensitivity and specificity, and 47 showed
greater sensitivity, specificity, accuracy, PPV, and NPV
than 1-hour PG. Among these 47 models [Table D13 in
(20)] were the multivariate model including HbA1c and
the panel of six metabolites (AHB, [Hyp3]-BK, mannose,
a-tocopherol, 10:1 carnitine, and X-12063); the model
including HbA1c, FPG, and six metabolites; and 10
different combinations of HbA1c and 30-minute PGwith
metabolites; 34 multivariate models that included the
combination of 1-hour PG and metabolites with or
without HbA1c and clinical risk factors; and a multi-
variate model including HbA1c, 2-hour PG, and five
metabolites. HbA1c was included in 28 of these models,
and clinical risk factors were included in six models.
The model including 1-hour PG and the panel of six
metabolites was among the 47 models that improved all
predictive performance measures over 1-hour PG. The
sparsest of the 47 models included 1-hour PG and
mannose. Moreover, mannose was included in the
highest number of models (44 out of 47). Thus, mannose
may be a crucial metabolic marker in combination with
other predictors such as 1-hour PG for assessing risk of
type 2 diabetes. Mannose, produced after the phos-
phorylation of glucose, is thought to be tightly linked to
the metabolism of glucose and fructose. Mannose alone
was comparable to 1-hour PG (q = 0.16). The potential of
mannose as a biomarker for type 2 diabetes has also been
shown previously (28, 29). However, routine use of
mannose or other metabolites for assessing the risk of
type 2 diabetes may not be possible in a clinical setting
until cost-effective assays become available.
Mannose correlated highly with FPG (r = 0.30) and
30-minute PG (r = 0.32). The other metabolites showed
higher correlation with post-OGTT PG values than with
FPG. The most striking example was AHB, which cor-
related poorly with FPG (r = 0.08) but more strongly with
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1-hour PG (r = 0.37). [Hyp3]-BK showed the strongest
negative correlation with 1-hour PG (r =20.25), whereas
X-12063 correlated the strongest with 2-hour PG (r =
0.35). The fact that the majority of metabolic markers
were more strongly correlated with postload glucose
values than with FPG suggests that metabolic markers
reflect stimulated (glucose) metabolism, unlike FPG
(30). On average, the metabolic marker panel showed
the highest correlation with 1-hour PG. The four
metabolic markers that highly correlated with 1-hour
PG (ie, mannose, AHB, [Hyp3]-BK, and X-12063) also
predicted progression to type 2 diabetes with similar
predictive performance as 1-hour PG (AUC = 0.75,
sensitivity = 0.68, specificity = 0.71, q = 0.53). These
results indicate that the metabolic marker signature
may capture key changes associated with response to
glucose stimulation. In accordance with these findings,
AHB and X-12063 have previously been shown to be
biomarkers of impaired glucose tolerance (31, 32). Ho
et al. (33) showed that AHB was among the metab-
olites altered in response to OGTT. Other studies have
reported AHB, mannose, and X-12063 as predictive
markers of type 2 diabetes (22, 28, 29, 32), and our
results showed that the combination of 1-hour PG,
AHB, mannose, and X-12063 (AUC = 0.80, sensi-
tivity = 0.76, specificity = 0.75) improved the pre-
dictive performance compared with the combination
of AHB, mannose, and X-12063 (q = 0.01) and 1-hour
PG (q = 0.03).
We provide strong evidence that 1-hour PG is a
robust predictor of future type 2 diabetes, together
with other reports based on large-scale epidemiologic
trials in different populations. The 1-hour PG signif-
icantly outperformed every individual marker except
for 30-minute PG, HbA1c, or mannose, which were
statistically comparable, albeit with lower AUC and
sensitivity. Adding metabolites improves the pre-
dictive value of 1-hour PG but significantly adds to
measurement costs. Nevertheless, our results show
that metabolic markers are robust predictors in com-
bination with PG measurements or HbA1c. In par-
ticular, mannose was identified as a crucial marker. It
is possible that metabolites could further improve the
predictive value of diabetic subgroups, because we
have recently shown that type 2 diabetes can be
subdivided into five subgroups with six clustering
variables (age at diagnosis, BMI, HbA1c, GAD au-
toantibodies, homeostatic model assessment of b-cell
function, and homeostatic model assessment of INS
resistance) with C-peptide measurements (34). The
predictive accuracy may also be further improved by
including additional anthropometric and lifestyle
data (35).
Limitations
The size of our study population (n = 543) diminishes
when divided into IFG/IGT (n = 198) and IFG/IGT-free
groups (n = 324), thus making it difficult to robustly
evaluate whether our findings hold true independent of
the IFG and IGT status at baseline. However, the pre-
dictive performances of the models we evaluated showed
similar trends as in the whole study population. Repli-
cation of our results in an independent study would
increase the value of our findings, but we were unable to
identify any study with all the measurements needed (ie,
clinical risk factors, HbA1c, PG, and INS measurements,
as well as the metabolic markers). However, our findings
related to the predictive performance of 1-hour PG have
been identified by other large-scale studies, as discussed
in this article, and we hope that our study forms a basis
for future validation studies by other researchers.
Conclusions
In summary, 1-hour PG is an effective biomarker for
predicting future type 2 diabetes either alone or in
combination withmetabolic markers. The 30-minute PG,
HbA1c, and mannose are statistically comparable to
1-hour PG, although they show slightly lower performance.
Metabolic markers provide a robust prediction of future
risk of type 2 diabetes in combination with postload PG
measurements and HbA1c. Shortening the standard 75-g
OGTT to 1 hour improves its predictive value and clinical
usability. International diabetes organizations should
consider this recommendation because 1-hour PG more
accurately identifies patients with dysglycemia, critical in
context of the burgeoning global population with obesity
and glucose disorders.
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